Study study type PathologyT1T0Patientssample sizesROB Results

mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population

versus interferon alpha
Ipilimumab (10 mg/kg)
E1609 (ipi10), 2020
  NCT01274338
RCTmML - NA - all populationipilimumab 10 mg/kgHDI high dose of interferon alphamelanoma of cutaneous or unknown primary origin (AJCC 7th edition stage IIIB, IIIC, or IV [M1a or M1b]) who were rendered disease free surgically. No priorsystemic adjuvant therapy was permitted.511 / 636high
inconclusive
  • inconclusive 12 % decrease in deaths (OS) (PE)
  • inconclusive 16 % decrease in RFS/DFS (PE)
ipilimumab alone
E1609 (ipi3), 2020
  NCT01274338
RCTmML - NA - all populationipilimumab 3 mg/kgHDI high dose of interferon alphamelanoma of cutaneous or unknown primary origin (AJCC 7th edition stage IIIB, IIIC, or IV [M1a or M1b]) who were rendered disease free surgically. No priorsystemic adjuvant therapy was permitted.523 / 636high
conclusif
  • demonstrated 22 % decrease in deaths (OS) (PE)
  • inconclusive 15 % decrease in RFS/DFS (PE)
versus Ipilimumab (10 mg/kg)
nivolumab alone
CheckMate 238, 2017
  NCT02388906
RCTmML - NA - all populationnivolumabipilimumabpatient, 15 years of age or older, with high-risk resected stage IIIB, IIIC, or IV melanoma as adjuvant treatment453 / 453low
conclusif
  • demonstrated 35 % decrease in RFS/DFS (PE)
  • suggested 27 % decrease in MFS
  • suggested 29 % decrease in RFS (extension)
versus nivolumab alone
nivolumab plus ipilimumab
IMMUNED (NI vs N) EXPLORATORY, 2020
  NCT02523313
RCTmML - NA - all populationnivolumab plus ipilimumabnivolumabadjuvant therapy with nivolumab alone or in combination with ipilimumab compared with placebo in patients with stage IV melanoma with no evidence of disease56 / 59low
inconclusive
  • suggested 60 % decrease in RFS/DFS
versus placebo
Ipilimumab (10 mg/kg)
EORTC 18071, 2015
  NCT00636168
RCTmML - NA - all populationipilimumab placebo patients with completely resected high-risk stage III melanoma who had not received previous systemic therapy for melanoma475 / 476low
conclusif
  • demonstrated 28 % decrease in deaths (OS) (PE)
  • demonstrated 25 % decrease in RFS/DFS (PE)
  • demonstrated 24 % decrease in MFS (PE)
  • suggested 27 % decrease in deaths (OS) (extension)
  • more...
nivolumab alone
IMMUNED (N vs P ; all population), 2020
  NCT02523313
RCTmML - NA - all populationnivolumabplaceboadjuvant therapy with nivolumab alone or in combination with ipilimumab compared with placebo in patients with stage IV melanoma with no evidence of disease59 / 52low
conclusif
  • demonstrated 44 % decrease in RFS/DFS (PE)
nivolumab plus ipilimumab
IMMUNED (NI vs P ; all population), 2020
  NCT02523313
RCTmML - NA - all populationnivolumab plus ipilimumabplaceboadjuvant therapy with nivolumab alone or in combination with ipilimumab compared with placebo in patients with stage IV melanoma with no evidence of disease56 / 52low
conclusif
  • demonstrated 77 % decrease in RFS/DFS (PE)
pembrolizumab alone
KEYNOTE 054 (all population), 2018
  NCT02362594
RCTmML - NA - all populationpembrolizumabplacebopatients with complete Resection of High-Risk Stage III Melanoma, stage IIIA, IIIB or IIIC melanoma with no in-transit metastases,514 / 505low
conclusif
  • demonstrated 43 % decrease in RFS/DFS (PE)
  • suggested 47 % decrease in MFS
  • suggested 44 % decrease in RFS (extension)
  • suggested 41 % decrease in RFS (extension)
  • more...